The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study

By sjmartinez • June 4, 2025

García-Estévez L, Bardia A, Rugo HS, Carey LA, Diéras VC, Loibl S, Piccart M, Gianni L, Kalinsky K, O'Shaughnessy J, Hurvitz SA, Harting E, Valdez T, Phan S, Lai C, Cortés J. The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study. ESMO Open. 2025 Jun 2;10(6):105294. doi: 10.1016/j.esmoop.2025.105294. Epub ahead of print. PMID: 40460679.

Tags: Antibody–drug conjugate, body mass index, Hematology/Oncology, metastatic triple-negative breast cancer, Obesity, Publications, Sacituzumab govitecan

Mirvetuximab Soravtansine Exposure and Incidence of Cataract Surgery

Silverstein JF, Smick A, Tsui E, Alomaja O, Johnson B, Tseng CH, Salani R, Slamon DJ, Chase DM, Konecny GE. Mirvetuximab Soravtansine Exposure and Incidence[...]

Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3

Nooka AK, Strouse C, Larson SM, Lesokhin A, Varshavsky-Yanovsky A, Vesole DH, Koehne G, Soussou E, Sullivan ST, Cheng J, Raje N. Efficacy and safety[...]

Five-Year Survival with Tebentafusp in Metastatic Uveal Melanoma

Piperno-Neumann S, Rutkowski P, Hassel JC, Butler MO, Schlaak M, Sullivan RJ, Dummer R, Kirkwood JM, Sacco JJ, Shoushtari AN, Piulats JM, Salama AKS, Orloff[...]